Results 51 to 60 of about 26,169 (207)

DENDRITIC CELL DIFFERENTIATION BLOCKED BY PRIMARY EFFUSION LYMPHOMA-RELEASED FACTORS IS PARTIALLY RESTORED BY INHIBITION OF P38 MAPK [PDF]

open access: yes, 2010
To better understand the molecular mechanisms underlying the dendritic cell (DC) defects in cancer, we analyzed which signaling pathway is implicated in the abnormal monocyte differentiation into DC determined by the presence of Primary effusion lymphoma
CIRONE, Mara   +6 more
core   +2 more sources

CD83 Modulates B Cell Activation and Germinal Center Responses [PDF]

open access: yesThe Journal of Immunology, 2016
Abstract CD83 is a maturation marker for dendritic cells. In the B cell lineage, CD83 is expressed especially on activated B cells and on light zone B cells during the germinal center (GC) reaction. The function of CD83 during GC responses is unclear.
Lena Krzyzak   +10 more
openaire   +2 more sources

The role of CD83 in the pathogenesis of immune thrombocytopenia

open access: yesHematology
Background CD83 are closely related to the pathogenesis of immune thrombocytopenia (ITP), but the exact mechanism remains unclear.Aim To explore the relationship between CD83 and CD4+ T cell subsets and clarify the role of CD83 in the pathogenesis of ITP.
Xiuli Wang   +14 more
doaj   +1 more source

Microsatellite unstable colorectal cancers are associated with increased CD1a- and CD83-positive dendritic cell infiltration

open access: yesBiotechnology & Biotechnological Equipment, 2023
Microsatellite instability (MSI) is characterized by a highly immunogenic tumor phenotype and abundant lymphocytic infiltrates. The aim of this study was to investigate the association between four immunohistochemically determined classes of dendritic ...
Maya Gulubova   +5 more
doaj   +1 more source

Nicotine strongly activates dendritic cell-mediated adaptive immunity - potential role for progression of atherosclerotic lesions [PDF]

open access: yes, 2003
Background - Antigen-presenting cells (APCs) such as monocytes and dendritic cells (DCs) stimulate T-cell proliferation and activation in the course of adaptive immunity.
Aicher, A   +5 more
core   +1 more source

A sustained decrease in serum CD83 in pregnant women

open access: yesJournal of Reproductive Immunology, 2022
Maternal immunity regulates tolerance to the semi-allogeneic fetus during pregnancy via modulation of immune regulatory factors. The serum factor CD83 is known to undergo changes during gestation in mice. Here we characterize serum levels of CD83 in women for the first time, revealing a consistent decline as pregnancy progresses and recovery to non ...
Kameliya Vinketova   +4 more
openaire   +2 more sources

Influenza Virus Neuraminidase Engages CD83 and Promotes Pulmonary Injury

open access: yesJournal of Virology, 2021
The massive release of circulating mediators of inflammation is responsible for lung injury during influenza A virus infection. This phenomenon is referred to as the “cytokine storm.” However, the mechanism by which influenza induces the cytokine storm is not fully understood.
Ning Ma   +5 more
openaire   +3 more sources

Unique Features and Distribution of the Chicken CD83+ Cell [PDF]

open access: yesThe Journal of Immunology, 2007
Abstract The central importance of dendritic cells (DC) in both innate and acquired immunity is well recognized in the mammalian immune system. By contrast DC have yet to be characterized in avian species despite the fact that avian species such as the chicken have a well-developed immune system. CD83 has proven to be an excellent marker
Chris, Hansell   +6 more
openaire   +2 more sources

CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential

open access: yesFrontiers in Immunology, 2019
CD83 is a member of the immunoglobulin (Ig) superfamily and is expressed in membrane bound or soluble forms. Membrane CD83 (mCD83) can be detected on a variety of activated immune cells, although it is most highly and stably expressed by mature dendritic
Ziduo Li   +13 more
doaj   +1 more source

Single‐Cell Level Characterization of B Cell Depletion and Repopulation Following Rituximab in Systemic Lupus Erythematosus

open access: yesArthritis &Rheumatology, EarlyView.
Objective Rituximab, a CD20+ B cell depletion therapy, is frequently used to treat systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation.
Haerin Jang   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy